Addendum
Bosutinib (chronic myelogenous leukaemia) - Addendum to Commission A21-79
Report documents
-
Addendum
Bosutinib (chronic myelogenous leukaemia) - Addendum to Commission A21-79
Dossier assessment
Indication:
Treatment of adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)
Result of dossier assessment:
Unchanged after addendum:
Hint of lesser benefit
Additional information
Federal Joint Committee (G-BA)
2021-11-19 A G-BA decision was published.
Project details
- Project no.
- A21-134
- Commission
- Commission awarded on 12.10.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed